
The chief scientific officer of a cannabis product company whose stock price has been hotter than a flaming joint (sorry) was known more than 18 months ago to have committed research misconduct while at the U.S. National Institutes of Health — casting a cloud of suspicion over the firm’s operations.
Marketwatch reported yesterday that the company, India Globalization Capital, which trades on the New York Stock Exchange as IGC, has at least nine other “red flags” for investors, from questions about its ability to manufacture cannabinoids to a history of trouble with the U.S. Securities and Exchange Commission.
Until August, the company’s stock had been trading below 50 cents per share. It began a dramatic rise, eventually reaching $13 per share. MarketWatch notes:




Tokyo Women’s Medical University has stripped a researcher of her PhD, following the retraction of a paper — for data duplication — that was based on her thesis.
A study that claimed a highly controversial “abortion reversal” method was effective — and which was temporarily removed from a journal’s site — has been republished.
A lab at the University of Malaya has lost two papers and will have to correct five more — just from one publisher — over poor lab practices.
For the second time in a week, we’ve come across a retraction notice that gave the wrong reason for the retraction.